2026-2034年全球青光眼市场规模、份额、趋势和成长分析报告

预计青光眼市场将从 2025 年的 98.6 亿美元成长到 2034 年的 151.2 亿美元，2026 年至 2034 年的复合年增长率为 4.87%。

由于与老龄化相关的眼科疾病盛行率不断上升以及全球老年人口的持续增长，全球青光眼市场正经历持续增长。人们对早期检测和治疗方案的认识不断提高，促使更多患者在适当的时候寻求医疗协助。诊断技术的进步和筛检计画的改进也推动了青光眼治疗方法和管理方案需求的成长。

关键成长要素包括新药製剂的研发、微创青光眼手术 (MIGS) 以及能够提高患者依从性的持续治疗方案。製药公司和医疗设备製造商不断增加的研发投入正在加速创新。此外，新兴市场眼科医疗服务可近性的提高正在扩大患者群体，并支持整体市场成长。

展望未来，诊断影像技术与人工智慧（AI）筛检工具的融合有望推动市场发展。联合疗法和个人化治疗方案的日益普及有望促进市场长期成长。随着医疗体係日益重视眼科预防保健和早期疗育策略，全球青光眼市场有望实现稳定永续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球青光眼市场：依疾病类型划分

• 市场分析、洞察与预测
• 开放性青光眼
• 隅角闭锁性青光眼
• 其他的

第五章 全球青光眼市场：依药物类别划分

• 市场分析、洞察与预测
• 前列腺素类似物
• β阻断剂
• 肾上腺素能促效剂
• 碳酸酐酶抑制剂
• 其他的

第六章 全球青光眼市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第七章 全球青光眼市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Pfizer Inc
  • Santen Pharmaceutical Co. Ltd
  • Novartis AG
  • Alcon Inc
  • Akron Operating Company LLC
  • Thea Pharma
  • AbbVie Inc
  • Bausch+Lomb Corporation
  • Teva Pharmaceutical Industries Ltd
  • Aerie Pharmaceuticals

The Glaucoma Market size is expected to reach USD 15.12 Billion in 2034 from USD 9.86 Billion (2025) growing at a CAGR of 4.87% during 2026-2034.

The Global Glaucoma Market is experiencing sustained growth due to the increasing prevalence of age-related eye disorders and the expanding geriatric population worldwide. Rising awareness about early detection and treatment options is encouraging more patients to seek timely medical care. Advancements in diagnostic technologies and improved screening programs are also contributing to the growing demand for glaucoma therapies and management solutions.

Key growth drivers include the development of novel drug formulations, minimally invasive glaucoma surgeries (MIGS), and sustained-release treatment options that enhance patient compliance. Increasing research and development investments by pharmaceutical and medical device companies are accelerating innovation. Furthermore, improved access to ophthalmic care in emerging markets is expanding the patient base and supporting overall market growth.

Looking forward, the market is expected to benefit from technological integration in diagnostic imaging and artificial intelligence-based screening tools. Growing adoption of combination therapies and personalized treatment approaches will likely drive long-term expansion. As healthcare systems emphasize preventive eye care and early intervention strategies, the glaucoma market is poised for steady and sustainable growth globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease Type

• Open Angle Glaucoma
• Angle Closure Glaucoma
• Others

By Drug Class

• Prostaglandins Analogs
• Beta-blockers
• Adrenergic Agonists
• Carbonic Anhydrase Inhibitors
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• Pfizer Inc, Santen Pharmaceutical Co Ltd, Novartis AG, Alcon Inc, Akron Operating Company LLC, Thea Pharma, AbbVie Inc, Bausch Lomb Corporation, Teva Pharmaceutical Industries Ltd, Aerie Pharmaceuticals
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GLAUCOMA MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Type
• 4.2. Open Angle Glaucoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Angle Closure Glaucoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GLAUCOMA MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Prostaglandins Analogs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Beta-blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Adrenergic Agonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Carbonic Anhydrase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GLAUCOMA MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Disease Type
  • 7.2.2 By Drug Class
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Disease Type
  • 7.3.2 By Drug Class
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Disease Type
  • 7.4.2 By Drug Class
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Disease Type
  • 7.5.2 By Drug Class
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Disease Type
  • 7.6.2 By Drug Class
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GLAUCOMA INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Pfizer Inc
  • 9.2.2 Santen Pharmaceutical Co. Ltd
  • 9.2.3 Novartis AG
  • 9.2.4 Alcon Inc
  • 9.2.5 Akron Operating Company LLC
  • 9.2.6 Thea Pharma
  • 9.2.7 AbbVie Inc
  • 9.2.8 Bausch + Lomb Corporation
  • 9.2.9 Teva Pharmaceutical Industries Ltd
  • 9.2.10 Aerie Pharmaceuticals